急性淋巴细胞白血病复发：生物标志物，希望和挑战。

IF 12.8 1区医学 Q1 BIOCHEMISTRY & MOLECULAR BIOLOGY

Trends in molecular medicine Pub Date : 2025-05-23 DOI:10.1016/j.molmed.2025.04.005

Joseph Adomako, Karina E Jiménez-Camacho, M Victor M Correa-Lara, Juan C Núñez-Enriquez, Michael Schnoor

{"title":"急性淋巴细胞白血病复发：生物标志物，希望和挑战。","authors":"Joseph Adomako, Karina E Jiménez-Camacho, M Victor M Correa-Lara, Juan C Núñez-Enriquez, Michael Schnoor","doi":"10.1016/j.molmed.2025.04.005","DOIUrl":null,"url":null,"abstract":"Acute lymphoblastic leukemia (ALL) is a rare disease in adults, but is the most common pediatric malignancy and the leading cause of death among children with cancer worldwide. While initial treatment regimens induce remission in most patients, relapses still occur in many cases during or after treatment. Relapses are difficult to treat and continue to be one of the leading causes of ALL-related deaths. Thus, it is essential to understand the biological mechanisms underlying ALL relapses, and to identify reliable biomarkers for better relapse risk prediction and novel druggable targets for precision treatments tailored to risk profiles. Here we review the latest developments in ALL research with a focus on relapse mechanisms, and we discuss related hopes and challenges.","PeriodicalId":23263,"journal":{"name":"Trends in molecular medicine","volume":" ","pages":""},"PeriodicalIF":12.8000,"publicationDate":"2025-05-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Acute lymphoblastic leukemia relapse: biomarkers, hopes, and challenges.\",\"authors\":\"Joseph Adomako, Karina E Jiménez-Camacho, M Victor M Correa-Lara, Juan C Núñez-Enriquez, Michael Schnoor\",\"doi\":\"10.1016/j.molmed.2025.04.005\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Acute lymphoblastic leukemia (ALL) is a rare disease in adults, but is the most common pediatric malignancy and the leading cause of death among children with cancer worldwide. While initial treatment regimens induce remission in most patients, relapses still occur in many cases during or after treatment. Relapses are difficult to treat and continue to be one of the leading causes of ALL-related deaths. Thus, it is essential to understand the biological mechanisms underlying ALL relapses, and to identify reliable biomarkers for better relapse risk prediction and novel druggable targets for precision treatments tailored to risk profiles. Here we review the latest developments in ALL research with a focus on relapse mechanisms, and we discuss related hopes and challenges.\",\"PeriodicalId\":23263,\"journal\":{\"name\":\"Trends in molecular medicine\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":12.8000,\"publicationDate\":\"2025-05-23\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Trends in molecular medicine\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1016/j.molmed.2025.04.005\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"BIOCHEMISTRY & MOLECULAR BIOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Trends in molecular medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.molmed.2025.04.005","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"BIOCHEMISTRY & MOLECULAR BIOLOGY","Score":null,"Total":0}

引用次数: 0

摘要

急性淋巴细胞白血病（ALL）是一种罕见的成人疾病，但却是最常见的儿科恶性肿瘤，也是世界范围内儿童癌症死亡的主要原因。虽然最初的治疗方案在大多数患者中引起缓解，但许多病例在治疗期间或治疗后仍会复发。复发很难治疗，并且仍然是all相关死亡的主要原因之一。因此，有必要了解ALL复发的生物学机制，并确定可靠的生物标志物，以更好地预测复发风险，并根据风险特征定制精确治疗的新药物靶点。在这里，我们回顾了ALL研究的最新进展，重点是复发机制，并讨论了相关的希望和挑战。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Acute lymphoblastic leukemia relapse: biomarkers, hopes, and challenges.

Acute lymphoblastic leukemia (ALL) is a rare disease in adults, but is the most common pediatric malignancy and the leading cause of death among children with cancer worldwide. While initial treatment regimens induce remission in most patients, relapses still occur in many cases during or after treatment. Relapses are difficult to treat and continue to be one of the leading causes of ALL-related deaths. Thus, it is essential to understand the biological mechanisms underlying ALL relapses, and to identify reliable biomarkers for better relapse risk prediction and novel druggable targets for precision treatments tailored to risk profiles. Here we review the latest developments in ALL research with a focus on relapse mechanisms, and we discuss related hopes and challenges.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Trends in molecular medicine 医学-生化与分子生物学

CiteScore

24.60

自引率

0.00%

发文量

142

审稿时长

6-12 weeks

期刊介绍： Trends in Molecular Medicine (TMM) aims to offer concise and contextualized perspectives on the latest research advancing biomedical science toward better diagnosis, treatment, and prevention of human diseases. It focuses on research at the intersection of basic biology and clinical research, covering new concepts in human biology and pathology with clear implications for diagnostics and therapy. TMM reviews bridge the gap between bench and bedside, discussing research from preclinical studies to patient-enrolled trials. The major themes include disease mechanisms, tools and technologies, diagnostics, and therapeutics, with a preference for articles relevant to multiple themes. TMM serves as a platform for discussion, pushing traditional boundaries and fostering collaboration between scientists and clinicians. The journal seeks to publish provocative and authoritative articles that are also accessible to a broad audience, inspiring new directions in molecular medicine to enhance human health.